Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.57 |
| ▸ | LMNA | P02545 | 4/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.57 |
| ▸ | MEN1 | O00255 | 7/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.55 |
| ▸ | RECQL | P46063 | 2/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.55 |
| ▸ | RAB9A | P51151 | 3/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.53 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.53 |
| ▸ | RELA | Q04206 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1960010 | 1.00 | MAPT (0.57) | MAPTLMNASMN1; SMN2MEN1KMT2A | |
| SCHEMBL1960006 | 1.00 | MAPT (0.57) | MAPTLMNASMN1; SMN2MEN1KMT2A | |
| SCHEMBL1958359 | 0.78 | MEN1 (0.60) | MAPTLMNASMN1; SMN2MEN1KMT2A | |
| SCHEMBL1958361 | 0.78 | MEN1 (0.60) | MAPTLMNASMN1; SMN2MEN1KMT2A | |
| SCHEMBL1958362 | 0.78 | MEN1 (0.60) | MAPTLMNASMN1; SMN2MEN1KMT2A | |
| SCHEMBL18032712 | 0.75 | MEN1 (0.57) | MAPTLMNASMN1; SMN2MEN1KMT2A | |
| SCHEMBL10476377 | 0.75 | MEN1 (0.60) | MAPTLMNASMN1; SMN2MEN1KMT2A | |
| SCHEMBL21023357 | 0.75 | MEN1 (0.66) | MAPTLMNASMN1; SMN2MEN1KMT2A | |
| SCHEMBL16532912 | 0.74 | MEN1 (0.66) | MAPTLMNASMN1; SMN2MEN1KMT2A | |
| SCHEMBL27983252 | 0.74 | MEN1 (0.82) | MAPTLMNASMN1; SMN2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2332905-B1 | BCRP/ABCG2 Inhibitor | YAKULT HONSHA KK (JP) | 2017-03-01 | — | — | EP | claimed |
| US-8697742-B2 | BCRP/ABCG2 inhibitor | KABUSHIKI KAISHA YAKULT HONSHA (JP) | 2014-04-15 | — | — | US | claimed |
| EP-2332905-A1 | BCRP/ABCG3 Inhibitor | Kabushiki Kaisha Yakult Honsha (JP) | 2011-06-15 | — | — | EP | claimed |
| US-20090253656-A1 | BCRP/ABCG2 INHIBITOR | KABUSHIKI KAISHA YAKULT HONSHA (JP) | 2009-10-08 | — | — | US | claimed |
| EP-1864972-A1 | BCRP/ABCG2 INHIBITOR | Kabushiki Kaisha Yakult Honsha (JP) | 2007-12-12 | — | — | EP | claimed |
| EP-2332905-B1 | BCRP/ABCG2 Inhibitor | YAKULT HONSHA KK (JP) | 2017-03-01 | — | — | EP | disclosed |
| US-8697742-B2 | BCRP/ABCG2 inhibitor | KABUSHIKI KAISHA YAKULT HONSHA (JP) | 2014-04-15 | — | — | US | disclosed |
| EP-2332905-A1 | BCRP/ABCG3 Inhibitor | Kabushiki Kaisha Yakult Honsha (JP) | 2011-06-15 | — | — | EP | disclosed |
| US-20090253656-A1 | BCRP/ABCG2 INHIBITOR | KABUSHIKI KAISHA YAKULT HONSHA (JP) | 2009-10-08 | — | — | US | disclosed |
| EP-1864972-A1 | BCRP/ABCG2 INHIBITOR | Kabushiki Kaisha Yakult Honsha (JP) | 2007-12-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090253656-A1 | BCRP/ABCG2 INHIBITOR | ABCC1, ABCB1, BRCA1 | MAPT 3660/4885LMNA 4321/4885SMN1; SMN2 4826/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.